METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced cancers? XL092 combo enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors (like kidney, prostate, lung, or colon cancer) that can't be removed by surgery. The main goals are to find safe doses and see if the treatment sh…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
New study checks kidney impact on prostate cancer drug safety
Disease control Recruiting nowThis study is for men with a certain type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It tests a radioactive drug called lutetium-177 vipivotide tetraxetan to see how the body handles it when kidneys are working normally or are impaired.…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
New drug combo targets tough prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see how the drug…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:47 UTC
-
New radiation drug targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called 3D1015 in men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to check safety and how the rad…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Chunjing Yu • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could gut bacteria be the key to fighting resistant prostate cancer?
Disease control Recruiting nowThis study tests whether adding a combination of antibiotics to the standard drug enzalutamide can help men with a type of advanced prostate cancer that no longer responds to hormone therapy. About 39 participants will receive the antibiotics for four weeks alongside enzalutamide…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for advanced prostate cancer: first human trial launches
Disease control Recruiting nowThis early-phase study tests a new drug, INR731, in about 208 men with metastatic prostate cancer that no longer responds to hormone therapy. The drug is given alone or with standard treatments to find a safe dose and check for side effects. The goal is to control the disease, no…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for tough cancers: experimental drug mevrometostat enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called mevrometostat in adults with advanced prostate cancer, small cell lung cancer, or follicular lymphoma that has stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New pill hopes to unleash immune system against tough cancers
Disease control Recruiting nowThis early-phase study tests an experimental pill called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug aims to boost the body's immune system to fight tumors. The main goals are to check safety and see if the drug can shrink or c…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope for tough prostate cancer: experimental drug AB-3028 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called AB-3028 in about 190 men whose prostate cancer has spread and stopped responding to standard hormone treatments. The main goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. Participants must have a s…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Arsenal Biosciences, Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Extra immunotherapy doses may strengthen prostate cancer fight
Disease control Recruiting nowThis early-phase study tests whether giving extra doses of the immunotherapy drug Sipuleucel-T can create a stronger immune response against advanced prostate cancer that has spread and no longer responds to hormone therapy. About 13 men will receive three infusions over 14 weeks…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New hope for tough prostate cancer: experimental drug opevesostat faces off against standard treatments
Disease control Recruiting nowThis study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard drugs (abiraterone or enzalutamide) in men with metastatic castration-resistant prostate cancer that got worse after one prior hormone treatment. About 1,314 participants will b…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Could green tea and quercetin boost chemo for advanced prostate cancer?
Disease control Recruiting nowThis study is for men with advanced prostate cancer that no longer responds to hormone therapy. It tests whether adding natural supplements (green tea and quercetin) to standard chemotherapy (docetaxel) can improve treatment. Researchers will compare the combination against a pla…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Charles Drew University of Medicine and Science • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
New Immune-Boosting drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called REGN5678, alone or with another drug (cemiplimab), in people with advanced prostate or kidney cancer that has spread. The goal is to find safe doses and see if the drugs can shrink tumors by helping the immune system attack cancer cells. About 3…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC